Semaglutide and Vision: What the Research and Regulators Say

Step 1: Recognise the two distinct ways semaglutide may affect your eyes

The first thing to separate is the difference between short-term, reversible visual changes and the rarer, more serious concern flagged in recent research.

Short-term blurry vision is documented on the NHS semaglutide medicines page as an infrequent side effect. It tends to appear in the early weeks of treatment, is usually mild, and is thought to be linked to shifts in blood glucose levels affecting the fluid balance inside the eye's lens. As the body adjusts, this typically resolves without treatment. It is not the same thing as optic nerve damage.

The more serious concern involves NAION (non-arteritic anterior ischaemic optic neuropathy) a sudden reduction in blood flow to the optic nerve that can cause permanent vision loss. This is already a known risk in the general population, particularly in people with cardiovascular risk factors. What the 2024 JAMA Ophthalmology study suggested was that this event appeared more frequently among people taking semaglutide than among matched controls. The study's authors were explicit: they could not rule out that pre-existing conditions common in people who take semaglutide, rather than the medicine itself, drove some of that signal. Regulatory bodies including the MHRA are actively monitoring the data, and our dedicated page on Wegovy and vision changes explains what that monitoring involves and what it means for people currently taking the medicine.

Knowing which category you may be in matters, because they call for different responses. If you're curious about whether and how Wegovy can affect your vision, that page sets out the evidence in full.

Step 2: Understand the NAION study and why it hasn't changed prescribing guidance yet

The JAMA Ophthalmology paper published in July 2024 looked at two groups: people with type 2 diabetes taking semaglutide versus those taking other diabetes medicines, and people with overweight or obesity taking semaglutide for weight management versus those taking non-GLP-1 medicines. In the weight-management group, semaglutide users had roughly a four-fold higher rate of NAION events, but the absolute numbers remained very small. NAION affects an estimated 2–10 people per 100,000 in the general population annually, so even a relative increase sits within a low absolute-risk range.

Regulatory agencies did not immediately revise prescribing information or issue restrictions in response to this study, partly because the study design (retrospective chart review) cannot establish whether semaglutide caused the events or whether the patient population using it carries higher baseline risk. Novo Nordisk said at the time that its own pharmacovigilance data did not support a causal link.

That does not mean this is settled. The evidence from the vision loss study is ongoing and regulators will update guidance if the signal strengthens in larger prospective data. In the meantime, the standard clinical advice holds: report sudden vision changes promptly and discuss your personal risk factors with your prescriber before starting treatment.

Step 3: Know the warning signs that need urgent attention

This is probably the most practically useful section, and it's worth being direct about it. Certain visual symptoms during semaglutide treatment should not be monitored at home or Googled further, they require same-day medical assessment.

Seek urgent help if you notice: sudden loss of vision in one or both eyes; a darkened or blurred area that appears in your visual field without warning; flashes of light or a curtain-like shadow across your sight; or any sudden eye pain. These are not typical GLP-1 side effects and should be assessed by an ophthalmologist or via A&E immediately. Our page on whether Wegovy causes vision problems, which covers the full range of reported ocular effects, includes each of these symptoms in more detail.

Milder symptoms (gradual mild blurring, occasional floaters you've had for years, dry eyes) are worth mentioning at your next clinical review but are rarely urgent. The distinction between sudden and gradual is the key one to hold in mind.

Anyone who suspects a side effect from semaglutide, including a vision-related one, can report it directly to the MHRA through the Yellow Card scheme. That reporting genuinely shapes how regulators update guidance, it is not just a formality.

Step 4: Talk to your prescriber before starting if you have relevant eye history

For most people, vision risk is not a reason to avoid semaglutide. For some, it is something that deserves a careful conversation first.

People with existing diabetic retinopathy fall into a specific group where the prescribing picture is more nuanced. Rapid improvement in blood glucose control, which semaglutide can produce, is sometimes associated with a temporary worsening of retinal changes. This is a known phenomenon and not unique to semaglutide, tight glycaemic control in general carries this risk. It does not mean the medicine is contraindicated, but it does mean your ophthalmologist and prescriber should be speaking to each other.

People with a history of optic nerve problems, ischaemic events or significant cardiovascular risk factors are also worth a more detailed discussion. The question of whether semaglutide can cause blurry vision depends partly on what's already happening in your eyes before you start, and if you'd like background on how the medicine is marketed and licensed, our page on the semaglutide trade name explains the difference between Ozempic, Wegovy and Rybelsus.

At nume, our clinical team reviews every consultation individually, a real prescriber reads your health history, not a form processor. If vision concerns are part of that history, they will factor into the clinical decision. If you'd like to explore treatment options and discuss your specific situation, you're welcome to speak to our prescribers.